Clinical Trial Detail

NCT ID NCT02698176
Title A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-small cell carcinoma

NUT midline carcinoma

triple-receptor negative breast cancer

prostate cancer

Therapies

Birabresib

Age Groups: child adult

No variant requirements are available.